Estée Lauder Forges Path in Science-Driven Beauty with Investment in 111SKIN
In a strategic move that underscores its commitment to science-driven beauty, The Estée Lauder Companies announced a minority investment in 111SKIN on April 29, 2026. This luxury clinical skincare brand was founded by the esteemed plastic surgeon, Dr. Yannis Alexandrides.
The London-based brand, established in 2012, was initially developed to expedite patient healing post-cosmetic procedures. The brand’s core is its proprietary NAC Y2™ complex, an innovative technology designed to bolster skin repair and sustain healthy, radiant, and resilient skin at the cellular level. This investment establishes Estée Lauder firmly within the rapidly expanding luxury clinical skincare segment, where consumers are increasingly seeking treatment-inspired results backed by clinical expertise.
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity, and beauty. Consumers are increasingly seeking products that deliver visible, treatment-inspired results,” stated Stéphane de La Faverie, President and CEO of The Estée Lauder Companies. The brand’s portfolio includes over 30 products, anchored by its Black Diamond and Reparative collections. North America accounted for approximately 40% of 2025 sales, with annual net sales estimated between $40-50 million.
Dr. Alexandrides will continue to helm 111SKIN, working alongside CEO Vanessa Goddevrind and the existing management team. This ensures the brand’s clinical authority remains intact. The investment mirrors Estée Lauder’s Beauty Reimagined strategy, which emphasizes consumer-centricity and transformative innovation in high-performance, preventative skincare.